Key Highlights

  • The Association of Clinical Research Professionals (ACRP) has updated all certification exams to align with the ICH E6(R3) global standard.
  • More than 45,000 certified professionals worldwide will need to meet the revised guidelines, marking a major update to Good Clinical Practice standards.
  • ICH E6(R3) introduces quality-by-design principles, risk-based approaches, and stronger participant protections, influencing trial design and compliance.
  • ACRP collaborated with subject matter experts to revise certification programs and training materials in preparation for the transition.

The clinical research sector is undergoing a significant transformation as the Association of Clinical Research Professionals (ACRP) updates its certification programs to align with the ICH E6(R3) global standards. This change will affect thousands of professionals and reshape how clinical trials are planned, monitored, and executed. The updated certification exams, including the ACRP-CP®, CCRA®, CCRC®, and CPI® credentials, now reflect the latest International Council for Harmonisation (ICH) guidelines, which emphasize risk-based quality management, modern trial methodologies, and enhanced participant safeguards.

This revision represents the first substantial update to Good Clinical Practice (GCP) standards in years, signaling a shift toward more adaptive and data-focused trial approaches.

Certification Overhaul Reflects Industry-Wide Regulatory Shift

ACRP’s adoption of ICH E6(R3) follows an extensive development process involving subject matter experts who redesigned core certification programs and specialty credentials to meet the new framework. The updated standards promote "quality by design," integrating risk assessment into trial planning rather than relying solely on post-trial compliance checks. This approach aims to minimize protocol deviations and streamline trial execution, particularly for sponsors utilizing decentralized or hybrid trial models.

To support professionals through this transition, ACRP has updated its training offerings and introduced an open-access resource center providing guidance on the new requirements. The move to ICH E6(R3) reflects a broader evolution in clinical trial oversight. The guidelines introduce more rigorous expectations for data integrity, real-time monitoring, and participant-centered trial designs, which may initially increase operational demands for sponsors.

However, the potential long-term benefits, such as fewer trial failures, faster approvals, and reduced regulatory challenges, could outweigh these costs. The updated exams will assess professionals’ proficiency in risk-based monitoring, digital health tools, and adaptive trial designs, skills that are increasingly valued in the pharmaceutical and research sectors.

Market Impact: Sponsors, Service Providers, and Technology Adoption

The certification update is expected to influence various stakeholders in the clinical trials ecosystem. Contract research organizations (CROs) and other service providers will need to adjust their internal processes to comply with the new standards, which may temporarily affect trial timelines. Organizations that rely on ACRP-certified professionals for compliance may face additional costs to ensure their teams meet the updated requirements.

Technology providers offering solutions for electronic trial documentation, monitoring platforms, and decentralized trial tools could see increased demand as sponsors seek to align with ICH E6(R3)’s emphasis on data integrity and real-time oversight. The guidelines’ focus on participant protection may also drive greater adoption of patient-centric technologies, such as remote monitoring devices and telehealth platforms, further expanding the digital health environment. For pharmaceutical sponsors, the transition may present short-term challenges as internal teams and external partners adapt to the new standards.

However, trials designed under ICH E6(R3) principles are expected to produce higher-quality data, reducing the likelihood of regulatory setbacks or post-approval complications. This could be particularly beneficial for companies developing advanced therapies, where trial design and data reliability are critical to success.

Next Steps: Implementation and Professional Development

ACRP has indicated that its focus will now shift to supporting professionals and organizations in implementing ICH E6(R3). The open-access resource center will serve as a central hub for best practices, case studies, and compliance tools, while updated training courses will emphasize practical applications of risk-based monitoring and quality-by-design principles. Certified professionals may need to complete additional continuing education to maintain their credentials, adding a new dimension to career development in the field.

The broader industry will closely monitor how regulatory agencies, including the FDA and EMA, apply the new standards in practice. The first real-world test of the updated guidelines will come as trials conducted under ICH E6(R3) begin submitting data for regulatory review. Until then, the emphasis will remain on training, technology integration, and operational adjustments to meet the new expectations.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.